PSMB9 and nasopharyngeal carcinoma: In EBV+ NPC, EBNA-1-and LMP2-specific CD8+ CTL responses can be suppressed in vitro by Tregs and their depletion with a recombinant fusion protein (Ontak) reverted this immune suppression (56).